Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MYCOPHENOLATE SODIUM vs AZATHIOPRINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Mycophenolate sodium is a prodrug that is hydrolyzed to mycophenolic acid (MPA), a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). IMPDH is a key enzyme in the de novo synthesis of guanine nucleotides, which is crucial for T- and B-lymphocyte proliferation. MPA preferentially inhibits the type II isoform of IMPDH expressed in activated lymphocytes, thereby exerting immunosuppressive effects.
Azathioprine is a purine analog that inhibits purine nucleotide synthesis, thereby suppressing DNA replication and cell proliferation. It is converted to 6-mercaptopurine, which acts as a purine antagonist, inhibiting de novo purine synthesis and interfering with RNA and DNA synthesis, particularly in rapidly dividing cells such as T-lymphocytes.
Prophylaxis of organ rejection in renal transplant patients receiving cyclosporine and corticosteroids,Prophylaxis of organ rejection in cardiac transplant patients (off-label),Prophylaxis of organ rejection in hepatic transplant patients (off-label),Treatment of lupus nephritis (off-label)
Renal transplant rejection prophylaxis (FDA),Rheumatoid arthritis (FDA),Off-label: autoimmune hepatitis, systemic lupus erythematosus, inflammatory bowel disease (Crohn's disease, ulcerative colitis), pemphigus, myasthenia gravis, dermatomyositis/polymyositis,Off-label: myelodysplastic syndrome, refractory immune thrombocytopenic purpura, atopic dermatitis, Behçet's syndrome
720 mg orally twice daily, administered as two 360 mg tablets or two 180 mg capsules. Intravenous infusion: 720 mg intravenously over 2 hours twice daily, for patients unable to tolerate oral therapy.
1.5 to 2.5 mg/kg orally once daily; typical adult dose 50-150 mg/day orally. Intravenous dose is 3-5 mg/kg/day as a slow infusion over 30-60 minutes.
The terminal elimination half-life of mycophenolic acid is approximately 8-16 hours in healthy subjects and renal transplant patients. The half-life of the inactive glucuronide metabolite (MPAG) is longer (16-18 hours) and accumulates in renal impairment.
Terminal elimination half-life of azathioprine is approximately 2–5 hours; its active metabolite 6-mercaptopurine has a half-life of 1–2 hours, but 6-thioguanine nucleotides accumulate in red blood cells with a half-life of several days, correlating with myelosuppression.
Mycophenolate sodium is a prodrug that is rapidly hydrolyzed in the gastrointestinal tract to the active metabolite mycophenolic acid (MPA). MPA is primarily metabolized by uridine diphosphate-glucuronosyltransferase (UGT) 1A9 to the inactive phenolic glucuronide (MPAG). A minor acyl glucuronide metabolite is also formed. MPAG is excreted in the urine and can be deconjugated back to MPA via enterohepatic recirculation.
Azathioprine is metabolized by xanthine oxidase (XO) and thiopurine methyltransferase (TPMT) to active (6-mercaptopurine) and inactive metabolites. 6-Mercaptopurine is further metabolized by XO to 6-thiouric acid and by TPMT to 6-methylmercaptopurine. Genetic deficiency of TPMT increases risk of toxicity.
Mycophenolate sodium is excreted primarily in urine as mycophenolic acid (MPA) and its glucuronide metabolite (MPAG). Renal excretion accounts for approximately 87% of the dose, with <1% excreted as unchanged MPA. Fecal excretion represents about 6%.
Renal (approximately 2% as unchanged drug, 30% as 6-thiouric acid and other metabolites); biliary/fecal (minor, <10% as metabolites).
Mycophenolic acid is 97% bound to serum albumin. The glucuronide metabolite (MPAG) is 82% bound.
Approximately 30% bound, primarily to albumin.
The apparent volume of distribution of mycophenolic acid is approximately 3.6 L/kg, indicating extensive tissue distribution. This large Vd reflects high tissue binding and distribution into extravascular spaces.
0.8–1.0 L/kg, indicating distribution into total body water; extensive distribution into tissues including liver and erythrocytes.
The oral bioavailability of mycophenolate sodium enteric-coated tablets is approximately 72% relative to intravenous mycophenolate mofetil. Food reduces peak concentration (Cmax) by 30-50% but does not significantly affect total area under the curve (AUC).
Oral bioavailability of azathioprine is 60–80% (mean 70%) with interindividual variability; absorption may be reduced by food.
For GFR 15-29 m L/min/1.73 m2: do not exceed 720 mg orally twice daily. For GFR <15 m L/min/1.73 m2: no data; use with caution. No adjustment for GFR >=30 m L/min/1.73 m2.
GFR >50 m L/min: no adjustment. GFR 10-50 m L/min: administer 75% of normal dose. GFR <10 m L/min: administer 50% of normal dose. Hemodialysis: administer 50% of normal dose after dialysis.
No specific dose adjustment guidelines for Child-Pugh class A, B, or C. Use with caution in severe hepatic impairment due to limited data.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 25-50%. Child-Pugh Class C: contraindicated or use with extreme caution; reduce dose by at least 50%.
Approved for pediatric renal transplant patients >=2 years: 400 mg/m2 orally twice daily (up to a maximum of 720 mg twice daily). For bone marrow transplant patients >=2 years: 400 mg/m2 orally twice daily, starting 24 hours after graft infusion.
1.5 to 2.5 mg/kg orally once daily; maximum 150 mg/day. For inflammatory bowel disease: 2-3 mg/kg/day. Intravenous: 3-5 mg/kg/day as a slow infusion.
No specific dose adjustment recommended; elderly patients may have increased risk of adverse effects such as gastrointestinal hemorrhage and infections. Use the lowest effective dose and monitor renal function closely.
Initiate at lower end of dosing range (1.5 mg/kg/day) due to potential for decreased renal and hepatic function; monitor renal function and hematologic parameters closely.
Increased risk of congenital malformations and first-trimester pregnancy loss when used during pregnancy. Females of reproductive potential must be counseled about pregnancy prevention and planning. Mycophenolate can cause fetal harm when administered to a pregnant woman. Use is contraindicated in women of childbearing potential who are not using highly effective contraception.
Malignancy: Patients receiving immunosuppressive therapy including azathioprine have an increased risk of developing lymphoma and other malignancies, particularly skin cancers. The risk is related to the duration and intensity of immunosuppression. Hematologic toxicity: Severe leukopenia, thrombocytopenia, and anemia, which may be dose-related, can occur. Regular monitoring of blood counts is required. Hepatotoxicity: Hepatotoxicity, including fatal liver injury, has been reported, particularly at high doses.
Immunosuppression: Increased susceptibility to infections, including opportunistic infections and reactivation of latent viruses (e.g., CMV, BK virus).,Lymphoproliferative disorders: Increased risk of post-transplant lymphoproliferative disorder (PTLD) and other malignancies.,Pregnancy: Associated with first-trimester pregnancy loss and congenital malformations; contraception counseling required.,Gastrointestinal events: Severe GI bleeding, perforation, and ulceration; monitor for symptoms.,Neutropenia: Can cause severe neutropenia; monitor complete blood counts regularly.,Vaccinations: Live vaccines should not be given during treatment; influenza vaccination may be less effective.
Hematologic monitoring: regular CBCs; Increased risk of infection; Hepatotoxicity; Pancreatitis; Carcinogenicity (lymphoma, skin cancer); TPMT deficiency increases myelotoxicity; Vaccination (live vaccines contraindicated); Renal and hepatic impairment; Drug interactions: allopurinol (reduce dose by 75%), ACE inhibitors (anemia), warfarin (anticoagulant effect decreased).
Hypersensitivity to mycophenolate sodium, mycophenolic acid, or any component of the formulation,Women of childbearing potential not using highly effective contraception,Pregnancy (unless no suitable alternative immunosuppressant is available)
Hypersensitivity to azathioprine or 6-mercaptopurine; Pregnancy (unless benefit outweighs risk) - Category D; Lactation; Patients with TPMT deficiency (increased risk of severe myelotoxicity); Severely depressed bone marrow function; Active infections; Concurrent use of live vaccines; Pre-existing malignancy (except in organ transplantation context).
Take on an empty stomach (1 hour before or 2 hours after meals) to minimize variability. Avoid grapefruit juice (may increase mycophenolate exposure). No specific dietary restrictions other than consistent timing relative to meals. High-fat meals reduce Cmax and AUC; administer consistently with or without food.
No known significant food interactions. Avoid grapefruit juice? (No interaction reported). Maintain consistent diet; no specific restrictions. Limit alcohol due to hepatotoxicity risk.
First trimester: High risk of structural malformations (e.g., cleft lip/palate, microtia, congenital heart defects) and spontaneous abortion. Second and third trimesters: Risk of oligohydramnios, intrauterine growth restriction, and preterm birth. Use is contraindicated in pregnancy unless no alternative.
Azathioprine is pregnancy category D. First trimester: increased risk of congenital anomalies including ventricular septal defects, limb defects, and esophageal atresia. Second and third trimesters: risk of intrauterine growth restriction, preterm birth, and neonatal immunosuppression (leukopenia, thrombocytopenia). Use only if benefit outweighs risk.
Enters breast milk; M/P ratio not established. Potential for serious adverse effects in nursing infants (e.g., immunosuppression, gastrointestinal disturbances). Contraindicated during breastfeeding.
Azathioprine is excreted into breast milk in low concentrations. M/P ratio is approximately 0.7. Nursing infants of mothers on azathioprine have not shown adverse effects; however, theoretical risk of immunosuppression exists. Caution is advised; monitor infant for increased infections.
Pharmacokinetic changes (increased clearance, decreased absorption) may require higher doses to maintain therapeutic levels; therapeutic drug monitoring recommended. Postpartum doses may need reduction due to changed pharmacokinetics.
Pharmacokinetic changes in pregnancy include increased clearance and decreased absorption. Dose may need adjustment to maintain therapeutic efficacy. Close monitoring of disease activity and drug levels (6-thioguanine nucleotide levels) is recommended. No standard dose adjustment; individualization required.
Monitor CBC weekly during first month, then biweekly for second and third months, then monthly for first year. Consider therapeutic drug monitoring (AUC 30-60 mg·h/L) to optimize dosing and reduce toxicity. Delayed-release formulation (Myfortic) must not be crushed or chewed. Avoid concurrent antacids or bile acid sequestrants. Dose reduction required in renal impairment (e GFR <50 m L/min). Estimate using ideal body weight. Taper when discontinuing to avoid graft rejection.
Monitor CBC and LFTs weekly for first month, then biweekly for 2 months, then monthly. TPMT genotype testing before initiation. Avoid concurrent allopurinol unless dose reduced to 25% of original. Use with caution in renal impairment. May cause hepatotoxicity, pancreatitis, or lymphoproliferative disorders.
Take exactly as prescribed; do not stop or change dose without consulting your transplant team.,Swallow delayed-release tablets whole; do not crush, chew, or cut them.,Use reliable contraception before, during, and for 6 weeks after treatment for females; males should use condoms during and for 90 days after treatment.,Avoid live vaccines (e.g., MMR, varicella) and close contact with recently vaccinated individuals.,Report signs of infection (fever, sore throat, chills), unexplained bruising/bleeding, or GI symptoms (nausea, diarrhea, abdominal pain).,Take on an empty stomach (1 hour before or 2 hours after meals) for consistent absorption.,Avoid grapefruit juice as it may alter drug levels.
Take exactly as prescribed; do not double dose if missed.,Avoid live vaccines during treatment and for 3 months after stopping.,Report any signs of infection, unexplained bruising/bleeding, or jaundice immediately.,Limit sun exposure and use sunscreen due to increased skin cancer risk.,Do not take allopurinol or other new medications without consulting doctor.,Maintain adequate hydration to reduce risk of hepatotoxicity.,Regular blood tests are required to monitor for side effects.
No interactions on record
"Azathioprine may reduce the therapeutic efficacy and cardiotoxic effects of digitoxin by accelerating its metabolism through induction of cytochrome P450 enzymes, particularly CYP3A4. This interaction can lead to decreased digitoxin serum concentrations, potentially resulting in loss of heart rate control in patients with atrial fibrillation or heart failure. Conversely, the cardiotoxic risk of digitoxin is diminished, but the therapeutic goal may be compromised."
"Azathioprine and fingolimod both suppress lymphocyte function, leading to additive or synergistic immunosuppression. This combination increases the risk of severe infections, including opportunistic infections, due to profound immune system suppression. Clinically, patients may present with prolonged lymphopenia, increased susceptibility to infections, and potential reactivation of latent viruses such as JC virus (causing progressive multifocal leukoencephalopathy) or cytomegalovirus."
"Azathioprine, an immunosuppressant that acts as a prodrug for 6-mercaptopurine, can increase the myelosuppressive effects of benazepril, an ACE inhibitor. This interaction is likely due to additive bone marrow suppression, leading to an elevated risk of leukopenia, anemia, and thrombocytopenia, especially in patients with renal impairment or concomitant use of other myelosuppressive agents."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MYCOPHENOLATE SODIUM vs AZATHIOPRINE, answered by our medical review team.
MYCOPHENOLATE SODIUM is a Immunosuppressant that works by Mycophenolate sodium is a prodrug that is hydrolyzed to mycophenolic acid (MPA), a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). IMPDH is a key enzyme in the de novo synthesis of guanine nucleotides, which is crucial for T- and B-lymphocyte proliferation. MPA preferentially inhibits the type II isoform of IMPDH expressed in activated lymphocytes, thereby exerting immunosuppressive effects.. AZATHIOPRINE is a Immunosuppressant that works by Azathioprine is a purine analog that inhibits purine nucleotide synthesis, thereby suppressing DNA replication and cell proliferation. It is converted to 6-mercaptopurine, which acts as a purine antagonist, inhibiting de novo purine synthesis and interfering with RNA and DNA synthesis, particularly in rapidly dividing cells such as T-lymphocytes.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MYCOPHENOLATE SODIUM and AZATHIOPRINE depend on the specific clinical indication. These are both Immunosuppressant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MYCOPHENOLATE SODIUM is: 720 mg orally twice daily, administered as two 360 mg tablets or two 180 mg capsules. Intravenous infusion: 720 mg intravenously over 2 hours twice daily, for patients unable to tolerate oral therapy.. The standard adult dose of AZATHIOPRINE is: 1.5 to 2.5 mg/kg orally once daily; typical adult dose 50-150 mg/day orally. Intravenous dose is 3-5 mg/kg/day as a slow infusion over 30-60 minutes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MYCOPHENOLATE SODIUM and AZATHIOPRINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MYCOPHENOLATE SODIUM is classified as Category C. First trimester: High risk of structural malformations (e.g., cleft lip/palate, microtia, congenital heart defects) and spontaneous abortion. Second and third trimesters: Risk of o. AZATHIOPRINE is classified as Category D/X. Azathioprine is pregnancy category D. First trimester: increased risk of congenital anomalies including ventricular septal defects, limb defects, and esophageal atresia. Second and. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.